Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights

Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights

Aspira Women's Health Inc.

Aspira Women’s Wellness Inc.

Preliminary tests quantity in the course of the fourth quarter of 2022 was 5,643, an increase of 18 {35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} compared to the fourth quarter of 2021

Preliminary final results consistent with previously supplied dollars utilization direction for the fourth quarter and comprehensive yr of 2022

Additional lowered employees to realize anticipated 12 months-more than-year salary charge personal savings of about $6 million in 2023

AUSTIN, Texas, Jan. 09, 2023 (Globe NEWSWIRE) — Aspira Women’s Wellbeing Inc. (“Aspira”), a bio-analytical based women’s well being organization focused on the progress of gynecologic illness diagnostic applications, right now announced preliminary fourth quarter highlights.

Preliminary Fourth Quarter Highlights

  • The selection of OvaSuiteSM exams executed elevated 23{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} to 21,424 assessments all through the year ended December 31, 2022, as opposed to 17,377 assessments in 2021.

  • The selection of OvaSuite checks carried out increased 18{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} to 5,643 exams in the course of the quarter ended December 31, 2022, when compared to 4,768 checks for the fourth quarter of 2021.

  • Common day-to-day check volume reached a new superior in the fourth quarter, escalating to 86.6.

  • Preliminary benefits reveal that Aspira has reached previously offered dollars utilization steerage for the fourth quarter of concerning $6 million and 8 million.

Aspira President and CEO, Nicole Sandford, said, “This yr-more than-12 months increase in test quantity demonstrates steady provider adoption and the developing have faith in in our Ova1Plus® ovarian cancer threat assessment exam. To further accelerate the trajectory of our OvaSuite products portfolio in 2023, we have determined our most impactful product sales and promoting procedures and have built quick changes to our methods as a outcome. Territories have been expanded for our most helpful industry associates, and we prepare to generate additional superior-touch medical professional instructional opportunities based mostly on the OvaWatch medical review a short while ago revealed in Frontiers in Drugs . We are also using techniques to keep on to greatly enhance our partnership with BioReference adhering to the prosperous start of our co-advertising and distribution arrangement in the fourth quarter.”

Ms. Sandford ongoing, “We proceed to make progress on price tag containment, and preliminary effects display we comfortably satisfied our earlier furnished money utilization guidance for the fourth quarter and entire yr of 2022. Such as the pressure reduction we executed very last 7 days, we hope to save additional than $6 million dollars, in addition the charge of rewards, in 2023 relevant to redundant roles. We do not assume these reductions to have a substance effects on our development ideas. We imagine our current sources and incremental revenue will maintain the company by means of its solution innovation and development goals in 2023,” Ms. Sandford concluded.

About Aspira Women’s Overall health Inc.
Aspira Women’s Overall health Inc. is transforming women’s gynecological wellbeing with the discovery, development, and commercialization of progressive testing options for ladies of all races and ethnicities. OvaSuite is the company’s portfolio of blood-based mostly ovarian most cancers risk evaluation checks designed to enable healthcare providers move confidently from assessment to action for gals with adnexal masses. Ova1Plus combines our Food and drug administration-cleared solutions, Ova1® and Overa®, to detect hazard of ovarian malignancy in females with adnexal masses prepared for operation. OvaWatchSM, a lab-formulated check with a 99{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} Adverse Predictive Value, was built to rule out ovarian cancer threat in people with masses that appear benign or indeterminate dependent on the clinician’s preliminary evaluation. EndoCheckTM, Aspira’s 1st-of-its-kind non-invasive diagnostic check for endometriosis, is now in growth. Visit our internet site for much more details at

Forward-On the lookout Statements
This push launch has ahead-on the lookout statements, as defined in the Personal Securities Litigation Reform Act of 1995, which include statements pertaining to strategic plans, development with respect to charge containment, believed examination volumes, estimated hard cash utilization for the fourth quarter and complete yr of 2022, hard cash means and anticipated financial savings and impacts from workforce reductions. Forward-seeking statements include a quantity of risks and uncertainties. Text these kinds of as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and comparable expressions are meant to determine ahead-on the lookout statements. These ahead-on the lookout statements talk only as of the date of this press release and are subject matter to a range of pitfalls, uncertainties and assumptions, together with those people described in the segment entitled “Risk Factors” in Aspira’s Once-a-year Report on Sort 10-K for the calendar year finished December 31, 2021, as supplemented by the part entitled “Risk Factors” in Aspira’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. Amid other items, there can be no assurance that Aspira’s precise whole calendar year 2022 financial and operating effects will not differ, potentially significantly, from the preliminary money and functioning results contained in this press release. In addition, Aspira has not accomplished its fourth quarter and comprehensive year 2022 closing and evaluate approach, and the remaining effects for the whole year 2022 might vary, most likely considerably, from the statements designed in this press release. In the course of the training course of planning our 2022 money statements and throughout our evaluate method, we might detect things that would require us to make adjustments that may perhaps be substance to the quantities described in this press launch. Genuine success could also differ from all those contemplated by ahead-searching statements due to challenges which include, but not limited to: our skill to proceed as a heading issue our potential to comply with Nasdaq’s continued listing needs impacts resulting from potential modifications to coverage of Ova1 by our Medicare Administrative Carrier for Ova1 impacts ensuing from or relating to the COVID-19 pandemic and actions taken to consist of it anticipated use of money and its results our capacity to enhance the quantity of our product or service profits failures by third-occasion payers to reimburse for our solutions and services or modifications to reimbursement premiums our potential to continue building present systems and to develop, safeguard and boost our proprietary technologies designs to establish and complete laboratory made checks our capacity to comply with Foods and Drug Administration (“FDA”) restrictions that relate to our merchandise and to get any Fda clearance or acceptance demanded to develop and commercialize professional medical units our skill to acquire and commercialize extra diagnostic items and accomplish current market acceptance with regard to these goods our potential to compete successfully our skill to obtain any regulatory acceptance required for our foreseeable future diagnostic goods or our suppliers’ skill to comply with Fda demands for manufacturing, promoting and submit-sector monitoring of our items our skill to maintain adequate or satisfactory supplies of immunoassay kits from our suppliers in the occasion that we do well in commercializing our items outside the United States, the political, financial and other circumstances influencing other countries improvements in healthcare plan our ability to comply with environmental legislation our means to comply with the further legislation and polices that implement to us in connection with the operation of ASPiRA LABS our capability to use our internet running loss carryforwards our capacity to use mental residence our skill to effectively defend our proprietary technology versus 3rd parties our means to attain licenses in the celebration a third get together effectively asserts proprietary legal rights the liquidity and buying and selling quantity of our frequent inventory the concentration of ownership of our frequent stock our skill to retain crucial personnel our potential to secure further capital on appropriate conditions to execute our company system business enterprise interruptions the performance and availability of our data systems our capability to integrate and obtain anticipated success from any acquisitions or strategic alliances upcoming litigation versus us, which includes infringement of mental assets and merchandise liability publicity and more costs that could be needed to make even further enhancements to our laboratory functions. The gatherings and situations mirrored in Aspira’s forward-on the lookout statements may perhaps not be obtained or come about, and true results could vary materially from all those projected in the ahead-hunting statements. Aspira expressly disclaims any obligation to update, amend or clarify any ahead-looking statements irrespective of whether as a result of new info, long term occasions or in any other case, other than as needed by law.

Trader Relations Speak to:
Monique Kosse
Running Director
LifeSci Advisors, LLC
Tel: 212-915-3820